Synopsis : Halozyme (NASDAQ: HALO) (“Halozyme”) today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement…
Research
-
-
Summary: Lipocine Inc. , a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that Antares…
-
CompaniesSun Pharma
Sun Pharma Acquires Uractiv portfolio from Fiterman Pharma in Romania
by adminby adminSummary Indian multinational pharma company Sun Pharmaceutical on Friday announced that one of its subsidiaries, S.C. Terapia S.A, has acquired the Uractiv…
-
World Environment 2022: The World Environment Day is celebrated on June 5 of each year with the aim to mark the importance of…
-
IndiaMerger / Acquisition
Dr. Reddy’s sells four Treatment Category Products to Torrent Pharma.
by adminby adminSummary : Torrent Pharmaceuticals, located in Ahmedabad, said on Thursday that it had agreed to buy four brands from Dr Reddy’s Laboratories…
-
Summary : The deal size is expected to be in the range of Rs 4,000-5,000 crore, sources close to the development .…
-
RegulatoryU.S FDA
TherapeuticsMD Receives U.S. Receives US Food and Drug Administration (FDA) Approval for the Supplemental New Drug Application (sNDA) for ANNOVERA
by adminby adminSummary : ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control – -With this approval, the Company expects a significant reduction…
-
CompaniesEli LillyRegulatoryU.S FDA
Eli Lilly Gets FDA Approval for Diabetic Drug Tirzepatide
by adminby adminSummary : The Food and Drug Administration (FDA) has approved a novel first-in-class drug to treat type 2 diabetes. The drug is…
-
Merger / Acquisition
Marksans Pharma acquires Access Healthcare for Medical Products L.L.C , Dubai for Rs 27 cr
by adminby adminSummary: Marksans Pharma signed a share purchase agreement to acquire a 100% stake in Access Healthcare for Medical Products L.L.C, a Dubai-based…
-
Daiichi SankyoRegulatoryU.S FDA
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki(Enhertu) for Breast Cancer
by adminby adminSummary: Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer…